Candida Antigen Immunotherapy Versus Steroid in the Treatment of Alopecia Areata

January 2021 in “ Dermatologic Therapy ”

Samia Taher Ali, Al‐shimaa M. Ibrahim, Noura El Sayed

Candida antigen immunotherapy steroid alopecia areata Candida albicans antigen triamcinolone acetonide intralesional steroids Candida antigen steroids AA Kenalog

From the encyclopedia

Alopecia Areata →

autoimmune disorder causing patchy hair loss

Triamcinolone Acetonide →

Studysummary This study found that intralesional Candida antigen was as effective as intralesional steroids for treating alopecia areata after 5 months, with significantly lower injection pain reported in the Candida group.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on onlinelibrary.wiley.com →

Discuss this study in the Community →

Research cited in this study

14 / 14 results

A Randomized Placebo-Controlled Single-Center Pilot Study of the Safety and Efficacy of Apremilast in Subjects with Moderate-to-Severe Alopecia Areata

research A Randomized Placebo-Controlled Single-Center Pilot Study of the Safety and Efficacy of Apremilast in Subjects with Moderate-to-Severe Alopecia Areata

42 citations , November 2018 in “Archives of dermatological research”

Apremilast was not effective in treating moderate-to-severe alopecia areata.

research What Is Behind the 'Swarm of Bees' in Alopecia Areata

7 citations , November 2018 in “British Journal of Dermatology”

Alopecia areata is caused by immune system issues, and JAK inhibitors might help treat it.

research Alopecia Areata: A Comprehensive Review of Pathogenesis and Management

99 citations , July 2017 in “Clinical Reviews in Allergy & Immunology”

This review noted that alopecia areata is an autoimmune disease impacting hair follicles and offered insights into its complex pathogenesis involving immune responses, while highlighting ongoing research into new treatments such as Janus kinase inhibitors and other immunomodulatory drugs.

research Treating Alopecia Areata: Current Practices Versus New Directions

26 citations , October 2016 in “American journal of clinical dermatology”

New treatments like JAK inhibitors show promise for reversing alopecia areata.

research Stem Cell Therapy as a Novel Therapeutic Intervention for Resistant Cases of Alopecia Areata and Androgenetic Alopecia

39 citations , August 2016 in “Journal of Dermatological Treatment”

This study observed that autologous bone marrow derived mononuclear cells and follicular stem cells were both safe and effective for improving resistant alopecia areata and androgenetic alopecia, with no serious adverse events.

research Benefit of Different Concentrations of Intralesional Triamcinolone Acetonide in Alopecia Areata: An Intrasubject Pilot Study

50 citations , July 2015 in “Journal of the American Academy of Dermatology”

This study found that 2.5 mg/mL triamcinolone acetonide injections were as effective as higher doses for treating limited, patchy alopecia areata, while minimizing side effects like skin atrophy.

research Alopecia Areata Update

85 citations , October 2012 in “Dermatologic Clinics”

This article reviews recent updates on alopecia areata, focusing on its causes, clinical presentation, and treatment options, and provides treatment plans by patient age and disease extent, but reports no new clinical results.

research Alopecia Areata: A New Treatment Plan

67 citations , July 2011 in “Clinical, cosmetic and investigational dermatology”

This review discusses various therapeutic agents for alopecia areata, categorized by efficacy and safety, and highlights the lack of curative treatments and long-term outcome studies.

research Alopecia Areata Update

244 citations , January 2010 in “Journal of the American Academy of Dermatology”

This review discusses treatment options for alopecia areata and suggests tailored treatment plans, noting the challenges posed by spontaneous remission and limited high-quality clinical trials.

research Topical Immunotherapy in Alopecia Areata

45 citations , January 2010 in “International journal of trichology”

This review examines topical immunotherapy for severe alopecia areata, noting that diphencyprone and squaric acid dibutylester are non-mutagenic options with similar efficacy but different practical considerations, and reports no new clinical results.

research Update on the Treatment of Alopecia Areata

11 citations , May 2009 in “Actas Dermo-Sifiliográficas”

This review discusses various therapeutic options for alopecia areata and reports no new clinical results; treatments may manage symptoms but do not cure the condition.

research Discoid Lupus Erythematosus Exacerbated by Contact Dermatitis Caused by Use of Squaric Acid Dibutylester for Topical Immunotherapy in a Patient with Alopecia Areata

15 citations , March 2008 in “The Journal of Dermatology”

In this case report, a patient with a history of discoid lupus erythematosus experienced an exacerbation of the condition after topical immunotherapy for alopecia areata, suggesting contact dermatitis as a potential trigger.

research Efficacy And Safety Of A New Clobetasol Propionate 0.05% Foam In Alopecia Areata: A Randomized, Double-Blind Placebo-Controlled Trial

114 citations , October 2006 in “Journal of the European Academy of Dermatology and Venereology”

In this study, clobetasol propionate foam demonstrated effectiveness and good patient compliance as a safe topical treatment for moderate to severe alopecia areata, with significant hair regrowth compared to placebo.

research Local Injection of Steroids and Hair Regrowth in Alopecias

57 citations , December 1960 in “Archives of Dermatology”

This introduction reviews historical use of steroids for alopecia treatment, mentioning early cases of hair regrowth with cortisone acetate but provides no new clinical data.